Home

NaamValutaDatumNAV 
J.LAMARCK BIOTECH Class AEUR23/02/2017325,30
J.LAMARCK BIOTECH Class BEUR23/02/2017306,57
J.Lamarck Biotech - Class CUSD23/02/2017329,27
J Lamarck Pharma - Class AEUR23/02/201789,09
J.Lamarck Biotech - Class DEUR23/02/2017106,18
J Lamarck Pharma - Class DEUR23/02/201791,52

 

 J. Lamarck Funds

De subfondsen genaamd Biotech en Pharma worden beheerd met behulp van beleggingsadvies van J. Lamarck SpA . J. Lamarck is een financiële dienstverlener opgericht in 1996 en gespecialiseerd in “biotech bedrijven”.

Sinds jaren, staat J. Lamarck voor hooggekwalificeerd advies gericht op het verstrekken van alle ondersteuning die nodig is om de beste resultaten uit beleggingen in de biotechnologie te krijgen.

De focus ligt voortdurend op de selectie van die biotech bedrijven die toekomstige leiders van de farmaceutische industrie zou kunnen worden. Het beleggingsbeleid is gericht op aandelenselectie en financiële analyse om de beste beleggingsportefeuille mogelijk te maken.

Read more →

 

Disclaimer

The information and opinions concerning funds and subfunds accessed through this link are not intended for consultation in those jurisdictions where these funds and subfunds are not registered or are otherwise unauthorised.

No information or opinion accessed through this link constitutes a solicitation, offer or recommendation to buy, sell or otherwise dispose of any investment, to engage in any other transaction or to furnish any investment advice or services.

Potential subscribers are advised to seek professional advice on the laws and regulations applicable to the subscription, purchase, holding, redemption and sale of shares in their countries of citizenship, residence or domicile.

No responsibility or liability is accepted regarding the accuracy, reliability or legality of any information whatsoever accessed through this site, or in respect of the contents of any website linked to the current site.

Past performance is not a guarantee of future returns. The value of investments may fall as well as rise.

Investors are expressly informed that this site provides information only, and that investment decisions should be made based on a full reading of the fund prospectus and the most recent financial statements.

Selecting the country of your residence will accept the conditions: